The September 21, 2017 amendments to the Patented Medicines (Notice of Compliance) Regulations (see our article here) introduced a new scheme for pharmaceutical patent linkage litigation in Canada. That scheme is now much closer to the US Hatch-Waxman scheme, but with remaining key differences, as shown in the chart below. A special thank you to Brian Coggio of Fish & Richardson for contributing the Hatch-Waxman details.
*revised September 2025.
Related Publications & Articles
-
Supreme Court of Canada reserves decision on appeal relating to the patentability of methods of medical treatment
Today, the Supreme Court heard oral arguments in Pharmascience Inc v Janssen Inc (Supreme Court File No 41209) and reserved its decision.Read More -
Ontario proposes legislation to regulate preferred provider networks
Following two public consultations with stakeholders, the Government of Ontario (Ministry of Finance) is moving forward with legislation to regulate preferred provider networks (PPNs).Read More -
PMPRB update: Guidelines for PMPRB Staff come into effect January 1, 2026; 2024 Annual Report
On January 1, 2026, the Guidelines for PMPRB Staff will come into effect. In November, the Patented Medicine Prices Review Board (PMPRB) held information sessions on the Guidelines to share technical ...Read More
